Merrimack Pharmaceuticals Inc. (Nasdaq: MACK) reported positive results from a Phase 3 trial of its post-gemcitabine metastatic pancreatic cancer treatment MM-398 in combination with 5-flourouracil and leucovorin. The stock price leaped $2.40 to $6.79.
Upbeat Trial Results For Merrimack Pharmaceuticals
May 01, 2014 at 12:54 PM EDT
